image credit: Janssen Cilag / Wikimedia

FDA approves Janssen’s Rybrevant

May 24, 2021


In the US, currently available targeted treatments such as EGFR tyrosine kinase inhibitors (TKIs) are not FDA-approved for treating NSCLC driven by EGFR exon 20 insertion mutations.

On top of that, NSCLC driven by this particular mutation often carries a worse prognosis and reduced survival rates compared with lung cancer driven by more common mutations.

“The approval of Rybrevant, along with the companion diagnostic test, addresses high unmet need in the treatment of people with genetically defined non-small cell lung cancer,” said Peter Lebowitz, global therapeutic area head, oncology, Janssen Research & Development.

Read More on Pharma Times